Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Cancer Immunol Res. 2014 Jun 9;2(9):901–910. doi: 10.1158/2326-6066.CIR-13-0123

Figure 3. Therapeutic immunizations with low doses of c-di-GMP and LM-Mb almost completely eliminated all metastases and improved T-cell responses in vitro and in vivo.

Figure 3

BALB/c mice received five therapeutic immunizations with low doses of c-di-GMP every day and LM-Mb every three days, according to Immunization protocol C. Nineteen days after tumor challenge mice were euthanized and analyzed for the number of metastases (A), tumor weight (B). In the same experiments, CD8 T-cell responses to Mage-b were analyzed in the spleen (pooled) in vitro by ELISPOT (C), or in blood (pooled) in vivo without any restimulation by flow cytometry (D). The results shown here are the averages of three independent experiments (n=5 mice per group). The error bars represent the SEM. In A and B, all groups were compared to LM-Mb + c-d-GMP. In C, all groups not depleted for CD8 T cells were compared to LM-Mb + c-di-GMP (star), and the CD8 T cell-depleted groups were compared to the same groups without CD8-depletion (rhombus). In D, all groups were compared to LM-Mb + c-di-GMP (*). Mann-Whitney test. *p<0.05, **<0.01, ***<0.001, ****<0.0001. Values p<0.05 were considered statistically significant.